000			01449 a2200421 4500
005			20250517122617.0
264		0	_c20181026
008			201810s 0 0 eng d
022			_a2168-6084
024	7		_a10.1001/jamadermatol.2016.3884 _2doi
040			_aNLM _beng _cNLM
100	1		_aTran, Duy C
245	0	0	_aFollow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma. _h[electronic resource]
260			_bJAMA dermatology _c01 2017
300			_a92-94 p. _bdigital
500			_aPublication Type: Letter
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aAntineoplastic Agents, Immunological _xtherapeutic use
650	0	4	_aCarcinoma, Squamous Cell _xdrug therapy
650	0	4	_aCell Death
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNivolumab
650	0	4	_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors
650	0	4	_aSkin Neoplasms _xdrug therapy
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aColevas, A Dimitrios
700	1		_aChang, Anne Lynn S
773	0		_tJAMA dermatology _gvol. 153 _gno. 1 _gp. 92-94
856	4	0	_uhttps://doi.org/10.1001/jamadermatol.2016.3884 _zAvailable from publisher's website
999			_c26552213 _d26552213